CClinicalTrials.gg
CompletedNCT05303311Updated Jul 30, 2024

Intrathecal Pethidine Plus Dexamethasone for Distal Lower Orthopedic Surgeries

A Phase 4 interventional study of Bupivacaine Hydrochloride and Pethidine plus Dexamethasone in Postoperative Pain, sponsored by Zagazig University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-30.

Sponsored by Zagazig University · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Bupivacaine is commonly used as a sole agent for spinal anesthesia unlike pethidine. Pethidine (meperidine) is a unique opioid. In addition to its analgesic activity, it also has significant local anesthetic activity. This property enables it to be used as the sole agent for spinal anesthesia

Read the detailed description

pethidine compared favorably with bupivacaine as the sole anesthetic agent, providing excellent conditions for lower abdominal and pelvic surgery. Some studies showed that intrathecal pethidine has short motor recovery and prolonged postoperative analgesia in comparison to intrathecal bupivacaine. The side effects of pethidine in spinal anesthesia are pruritus nausea, vomiting and respiratory depression. A dose of 1mg/kg intrathecal pethidine provides surgical anesthesia .However, its effects are not widely available in recent studies.

Dexamethasone is used as an adjuvant to local anesthetic during spinal anesthesia and other techniques of regional anesthesia, it reduces pain and prolongs the duration of post-operative analgesia. It was shown that intrathecal dexamethasone reduces the complications of spinal anesthesia such as arterial hypotension, nausea, vomiting and shivering. The investigators suppose that addition of intrathecal dexamethasone to pethidine may be a better alternative to intrathecal bupivacaine during spinal anesthesia for lower extremity orthopedic surgery with better outcome and less side effects

02

Conditions studied

  • Postoperative Pain

Browse trials for

03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 46 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Zagazig University is the lead sponsor of 447 studies on the registry; 75 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patient acceptance.
  • Patients scheduled for lower extremity orthopedic surgery
  • Both sex
  • Patient's age >18 years.
  • Patients with American Society of Anaesthesia (ASA)physical status I, II.

Exclusion criteria

Exclusion Criteria:

  • Patient's age ≤18 years.
  • Uncooperative patients and patients with psychological problems.
  • Patients with contraindications to spinal anesthesia.
  • Patients with contraindications to bupivacaine or dexamethasone or pethidine.
  • Patients with ASA physical status III and IV.
  • Morbid obesity (BMI >35).
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
46 participants (actual)

Study arms

  • Active comparator
    Bupivacaine group

    Patients will be anesthetized by spinal anesthesia by intrathecal injection of 3 ml hyperbaric bupivacaine 0.5% alone.

    Drug: Bupivacaine Hydrochloride

  • Active comparator
    pethidine plus dexamethasone group

    Patients will be anesthetized by spinal anesthesia by intrathecal injection of 1mg/kg preservative-free pethidine plus 4mg dexamethasone diluted to a volume of 3 ml with 0.9% sodium chloride

    Drug: Pethidine plus Dexamethasone

Interventions

  • DrugBupivacaine Hydrochloride

    intrathecal injection of bupivacaine alone

    Also known as: Heavy marcaine

  • DrugPethidine plus Dexamethasone

    Intrathecal injection of pethidine plus dexamethasone

    Also known as: meperidine and decadron

06

What researchers measure

Primary outcomes

  1. The Time of the first need for Rescue Analgesia

    the time from the end of the intrathecal injection of the study drugs to the first report of pain that reached NRS 4 as described by the patient.

    Time frame: 24 hours postoperative

Secondary outcomes

  1. Intraoperative changes in the blood pressure measurements (The incidence of hypotension )

    The incidence of hypotension "defined as the mean arterial blood pressure decreased by \> 20 % from its value before intrathecal injection of the study drugs"

    Time frame: duration of the procedure

  2. Intraoperative changes in the heart rate measurements (The incidence of bradycardia)

    bradycardia "defined as the reduction of heart rate by \> 20% of the basal reading".

    Time frame: duration of the procedure

  3. The onset of the sensory block

    The sensory level was checked using the pinprick technique every min for 10 min then at 2-min intervals until a constant block was obtained

    Time frame: duration of the procedure

  4. The onset of the motor block

    The Motor Block was checked using Modified Bromage Score "Bromage 0 means full movement of the hip, knee, and ankle, Bromage 1 means loss of the ability to raise the leg against gravity but able to bend the knee and the ankle joints, Bromage 2 lost the ability to flex the hip and knee joints but preserved flexion of the ankle, Bromage 3 lost the ability to flex the hip, knee, and ankle joints but preserved movement of the toes, Bromage 4 indicates full paralysis of the legs". every min for 10 min then at 2-min intervals until a Bromage score 4 was obtained

    Time frame: duration of the procedure

  5. The time of regression of sensory block to the 5th lumbar dermatome

    The sensory level was checked using the pinprick technique every 15 min until sensations were gained back to the 5th lumbar dermatome

    Time frame: Up to 12 hours postoperative

  6. The time of regression of motor block to full motor function "Bromage score 0".

    The Motor Block was checked using Modified Bromage Score every 15 min until full motor function was restored. "Bromage score 0"...... Modified Bromage Score: "Bromage 0 means full movement of the hip, knee, and ankle, Bromage 1 means loss of the ability to raise the leg against gravity but able to bend the knee and the ankle joints, Bromage 2 lost the ability to flex the hip and knee joints but preserved flexion of the ankle, Bromage 3 lost the ability to flex the hip, knee, and ankle joints but preserved movement of the toes, Bromage 4 indicates full paralysis of the legs".

    Time frame: Up to 12 hours postoperative

  7. The incidence of perioperative adverse events

    Assess the frequency of perioperative nausea, vomiting, sedation, shivering, pruritis, and respiratory depression.

    Time frame: duration of the procedure and 24 hours postoperative

07

Study locations

1 site
  • Faculty of Medicine , Zagazig University
    Zagazig, Sharkia 44511, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05303311
Lead sponsor
Zagazig University
Responsible party
Salwa Samir El Sherbeny (Lecturer of Anesthesia, Intensive Care and pain management, Faculty of Medicine, Zagazig University, Zagazig University) — Principal investigator
First posted
Mar 31, 2022
Start date
Jan 15, 2022
Primary completion
Jan 15, 2024
Completion
Mar 15, 2024
Last update
Jul 30, 2024

Study contacts

Salwa S ElSherbeny, Lecturer
principal investigator · Zagazig University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion